

Formulary Drug Monograph
GENERIC NAME (Brand, Manufacturer)

Evidence Table Draft

Your Name Here, PharmD (Candidate)

References

1. Risedronate prescribing information. Procter & Gamble Pharmaceuticals, Cincinnati, Ohio 45202. 2000.
2. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. *Osteoporos Int* 2000; 11(1): 83-91.
3. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. *Osteoporos Int* 2000; 11(4): 331-337.
4. Reid DM, Hughes RA, Laan R, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *J Bone Mineral Res* 2000; 15(6): 1006-13.
5. Harris, ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. *JAMA* 1999; 282(14): 1344-52.
6. Manuscript in publication; data on file with Procter and Gamble and Aventis.
7. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet* 1996;348:1535-1541.